by
Joan Trombetti, Writer | March 19, 2008
Xoft, Inc. has received expanded clearance from the FDA for the Axxent® Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radiation treatment in minimally shielded clinical settings.
The Axxent System was cleared for accelerated treatment of early stage breast cancer and is now cleared for treatment of other cancers or conditions where radiation therapy is warranted.
Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications. These are pending FDA clearance. As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.
The Axxent treatment platform can be used in any clinical setting under the supervision of a radiation oncologist and is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. This eliminates the need for heavily shielded environments and gives radiation oncologist the flexibility to deliver therapy in a broader range of clinical settings.
The Axxent Electronic Brachytherapy System also provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.
About Xoft, Inc.
Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.
